Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
We focus on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
At Amgen Hong Kong, we provide 14 innovative and high-quality treatments and biosimilar medicines in support of nearly 40,000 patients in Hong Kong and Macau in 2021 across six therapeutic areas: bone health, cardiology, oncology, rheumatology, inflammatory and hematology.
Amgen applies the highest standards of scientific research to all its products and is committed to investing in clinical trials to ensure that products are recognized by governments, medical professionals and patients in the region. With over four decades of biologics R&D experience, we leverage our heritage of scientific innovation and devote the same attention to detail, skills, experience and manufacturing excellence to all our products. Our robust pipeline of medicines in clinical development includes treatments for bone disease, cardiology, oncology, rheumatology, inflammatory and hematology.
Amgen is committed to invest in clinical trials in Asia and has five clinical trial hubs in the region, with 175 active studies, 1,342 active sites, and 2,723 subjects as of July 2022. Hong Kong has been a key clinical development hub for Amgen in the Japan and Asia Pacific (JAPAC) region since 2007, facilitating collaboration between Amgen and local researchers, and leveraging their expertise to advance our clinical pipeline.
The treatment of millions of patients worldwide relies on the safe and reliable production of biologic medicines. The development of biologic drugs is a complex and demanding process that requires specialized skill and experience. As a global leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering innovative and high-quality medicines to Asian patients. This record of success is supported by state-of-the-art facilities and global manufacturing network, as well as regional capabilities to ensure quality and supply. At Amgen, we understand that quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.
Biosimilars development is equally complex. As such, Amgen leverages its innovator biologics expertise to manufacture quality biosimilar medicines. We use the same processes, scientific standards, and quality systems for our biosimilars as we do for our innovator biologics. Our leadership as a biosimilar producer continues to provide more options to the patients, helping to make the healthcare system more sustainable.
Date of Approval: July 2022